Trifluoromescaline

Trifluoromescaline, also known as 4--3,5-dimethoxyphenethylamine, is a derivative of the phenethylamine psychedelic mescaline, which has a 4-trifluoromethoxy group replacing the 4-methoxy group of mescaline. It was found to be one of the most potent compounds in the scaline series, with a reported dose of 15 to 40mg, and a slow onset of action and long duration of effects, lasting 14 to 24hours or more. The drug showed about 36-fold greater activational potency at the serotonin 5-HT_2A receptor compared to mescaline in vitro. In addition, it appears to be much more lipophilic than mescaline. TFM was first described in the scientific literature by Daniel Trachsel by 2012. Many other related compounds have also been described by Trachsel and colleagues. It is not a controlled substance in Canada as of 2025.